Welcome to our dedicated page for Jasper Therapeutics news (Ticker: $JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jasper Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jasper Therapeutics's position in the market.
Jasper Therapeutics (Nasdaq: JSPR), a biotechnology company developing briquilimab for mast cell-driven diseases, announced its Q1 2024 financial results and corporate updates.
Key progress includes enrollment in Phase 1b/2a BEACON and SPOTLIGHT studies for chronic urticarias, with initial data expected in Q3 and H2 2024.
Jasper is also advancing briquilimab for asthma, starting enrollment in Q4 2024.
Financially, Jasper reported a net loss of $13.7 million, with cash reserves of $118.5 million, extending its runway through Q3 2025 after a $50 million stock offering in February 2024.
Other developments include positive data on briquilimab for CGD and MDS, and the issuance of inducement stock options to new employees.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the initiation of a Phase 1b/2a study evaluating briquilimab in asthma patients in Q4 2024. Briquilimab targets mast cell-driven diseases like chronic spontaneous urticaria and chronic inducible urticaria. The company presented promising preclinical data at the recent AAAAI annual meeting, demonstrating the depletion of mast cells in the airways and prevention of allergen-induced asthmatic responses. Jasper plans to host a KOL webinar on May 20, 2024, featuring Professor Joshua Boyce to discuss the potential of briquilimab in asthma.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) will present at upcoming investor conferences in May to discuss the development of briquilimab, a novel antibody therapy addressing mast cell driven diseases. The company's management will participate in panel discussions at Capital One Securities Biotech/Biopharma Disruptors Event and in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference.